Organogenesis (ORGO) Competitors

Organogenesis (NASDAQ:ORGO) and Vericel (NASDAQ:VCEL) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, community ranking, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Which has more volatility & risk, ORGO or VCEL?

Organogenesis has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500.

Do analysts prefer ORGO or VCEL?

Organogenesis presently has a consensus price target of $5.50, indicating a potential upside of 30.33%. Vericel has a consensus price target of $60.86, indicating a potential upside of 47.60%. Given Vericel's stronger consensus rating and higher possible upside, analysts plainly believe Vericel is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vericel	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to ORGO or VCEL?

In the previous week, Vericel had 10 more articles in the media than Organogenesis. MarketBeat recorded 12 mentions for Vericel and 2 mentions for Organogenesis. Vericel's average media sentiment score of 1.34 beat Organogenesis' score of 0.86 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	11 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger valuation & earnings, ORGO or VCEL?

Organogenesis has higher revenue and earnings than Vericel. Organogenesis is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$482.04M	1.11	$4.95M	-$0.02	-211.00
Vericel	$237.22M	8.71	-$3.18M	$0.18	229.06

Do insiders & institutionals have more ownership in ORGO or VCEL?

49.6% of Organogenesis shares are owned by institutional investors. 36.9% of Organogenesis shares are owned by company insiders. Comparatively, 7.2% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Is ORGO or VCEL more profitable?

Vericel has a net margin of 1.56% compared to Organogenesis' net margin of -1.62%. Vericel's return on equity of 1.48% beat Organogenesis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-1.62%	-2.69%	-1.63%
Vericel	1.56%	1.48%	0.96%

Does the MarketBeat Community prefer ORGO or VCEL?

Vericel received 258 more outperform votes than Organogenesis when rated by MarketBeat users. However, 65.99% of users gave Organogenesis an outperform vote while only 61.85% of users gave Vericel an outperform vote.

Company	Underperform	Outperform
Organogenesis	Outperform Votes 97 65.99%	Underperform Votes 50 34.01%
Vericel	Outperform Votes 355 61.85%	Underperform Votes 219 38.15%

Summary

Vericel beats Organogenesis on 12 of the 18 factors compared between the two stocks.